Aurinia Pharmaceuticals Q2 revenue up 22%, raises guidance
Overview
Aurinia Q2 2025 total revenue rises 22% yr/yr to $70 mln
Net income for Q2 2025 reaches $21.5 mln, up from $0.7 mln last year
Co increases share repurchase plan by $150 mln, reflecting financial confidence
Outlook
Aurinia raises 2025 revenue guidance to $260 mln-$270 mln
Company ups 2025 LUPKYNIS sales forecast to $250 mln-$260 mln
Aurinia plans clinical trials for aritinercept in autoimmune diseases
Company sees growth driven by new lupus nephritis treatment guidelines
Result Drivers
LUPKYNIS SALES - Co attributes 21% increase in net product sales to new treatment guidelines recommending LUPKYNIS as first-line therapy
COLLABORATION REVENUE - License, collaboration and royalty revenue up 55% due to manufacturing services from partner Otsuka
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Product Revenue |
| $66.57 mln |
|
Q2 EPS |
| $0.16 |
|
Q2 Net Income |
| $21.51 mln |
|
Q2 Operating Expenses |
| $49.92 mln |
|
Q2 Operating Income |
| $20.08 mln |
|
Q2 Pretax Profit |
| $22.16 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Aurinia Pharmaceuticals Inc is $10.85, about 16.6% above its July 30 closing price of $9.05
The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 15 three months ago
Press Release: ID:nBw74Sx5Ga
